When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.jCr9XYTz.js ...

GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

A class of drugs designed to fight diabetes and weight loss can help with a host of other problems, but also carry some side effects.

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like ...

We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...